Enanta Pharmaceuticals | ENTA - Ordinary Share Capital


Enanta Pharmaceuticals reported $212K in Ordinary Share Capital for its fiscal quarter ending in December of 2023.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Amgen USD 541M 1000K Jun/2026
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 141.14M 564K Jun/2026
AstraZeneca USD 1.55B 44K Jun/2026
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
Biogen USD 146.7M 200K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
Halozyme Therapeutics USD 114.04M 4.48M Jun/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Immunic USD 120.38M 21.73M Dec/2025
Incyte USD 200.98M 1.03M Jun/2026
Insmed USD 218.28M 1.76M Jun/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
J&J USD 2.41B 1.35M Mar/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
Merck USD 2.47B 4.93M Mar/2026
Neurocrine Biosciences USD 100.55M 50K Jun/2026
Novartis USD 1.9B 7.38M Jun/2026
Novavax USD 162.58M 106K Dec/2025
Pfizer USD 5.7B 0 Jun/2026
PTC Therapeutics USD 82.88M 1.41M Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sarepta Therapeutics USD 105.62M 53K Jun/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026